Jupiter Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Jupiter Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,755	Closed	-$421K	–	435
2024 Q1	$421K	Hold	5,755	–	–	﹤0.01%	396
2023 Q4	$411K	Hold	5,755	–	–	﹤0.01%	419
2023 Q3	$345K	Hold	5,755	–	–	﹤0.01%	449
2023 Q2	$414K	Hold	5,755	–	–	﹤0.01%	465
2023 Q1	$422K	Hold	5,755	–	–	0.01%	380
2022 Q4	$384K	Sell	5,755 -3,470	-38%	-$226K	0.01%	419
2022 Q3	$496K	Hold	9,225	–	–	0.01%	436
2022 Q2	$512K	Sell	9,225 -16,285	-64%	-$924K	0.01%	487
2022 Q1	$1.79M	Sell	25,510 -467	-2%	-$33.9K	0.02%	362
2021 Q4	$2.53M	Sell	25,977 -2,569	-9%	-$237K	0.03%	326
2021 Q3	$2.48M	Hold	28,546	–	–	0.03%	325
2021 Q2	$2.33M	Hold	28,546	–	–	0.02%	377
2021 Q1	$2.71M	Sell	28,546 -18,749	-40%	-$1.77M	0.03%	380
2020 Q4	$2.93M	Buy	+47,295	New	+$2.7M	0.03%	384

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Jupiter Asset Management's LGND Position: Q2 2024 in Review

Jupiter Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 5,755 shares — an estimated $421K sold.

Jupiter Asset Management first reported a position in LGND in Q4 2020 and held it in 14 quarters. The position peaked at $2.93M in Q4 2020. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

Jupiter Asset Management reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Jupiter Asset Management sold 5,755 Ligand Pharmaceuticals shares in Q2 2024, an estimated $421K.
Jupiter Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2020 and held it in 14 quarters.
Jupiter Asset Management's Ligand Pharmaceuticals position peaked at $2.93M in Q4 2020.
234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on Jupiter Asset Management's 13F filing for Q2 2024, filed 8 Aug 2024.